NCT06735807

Brief Summary

Emotional Distress, such as anxiety and depression, is an essential issue worldwide. There have been several evidence-based psychotherapies that are effective in improving emotional distress, such as Acceptance and Commitment Therapy (ACT). However, the scarcity of professionals and the imbalance in the distribution of mental health resources prevent individuals in need from accessing immediate and effective help. Artificial intelligence (AI) has the potential to promote this problem. The existing studies have provided preliminary support for the application of AI in mental health interventions. One such model, Emohaa, a generated AI model, has been examined for its effectiveness in adult emotional distress. However, despite the limited reliability of the single-group design, parallel randomized controlled trials are scarce to validate this finding further. This present study is to fill this gap. This study aims to examine the effectiveness of the generated AI (Emohaa) in reducing emotional distress, including anxiety and depression, compared with group ACT and waitlist. In this parallel randomized controlled trial, it is hypothesized that (1) Compared with the waitlist, Emohaa and group ACT could significantly improve participants' emotional distress, including anxiety and depression symptoms; (2) Emohaa would lead to a greater reduction in anxiety and depression symptoms compared with group ACT.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 20, 2024

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

December 6, 2024

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 16, 2024

Completed
4 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 20, 2024

Completed
8 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 28, 2024

Completed
Last Updated

April 25, 2025

Status Verified

September 1, 2024

Enrollment Period

3 months

First QC Date

December 6, 2024

Last Update Submit

April 24, 2025

Conditions

Outcome Measures

Primary Outcomes (8)

  • Patient Health Questionnaire (PHQ-9)

    PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring, and measuring the severity of depression. Questions are scored on a Likert scale of 0-3 with 0 being not at all and 3 being nearly every day.

    0, 2, 4, 6, 8, and 10 weeks

  • Generalized Anxiety Disorder (GAD-7)

    GAD-7 is an easy-to-perform initial screening tool for generalized anxiety disorder. Questions are scored on a Likert scale of 0-3 with 0 being not at all and 3 being nearly every day.

    0, 2, 4, 6, 8, and 10 weeks

  • UCLA Loneliness Scale (ULS-3)

    ULS-3 is a brief version of the UCLA Loneliness Scale with 3 items, which was designed to assess loneliness. Questions are scored on a Likert scale of 1-4 with 1 being never and 4 being always.

    0, 2, 4, 6, 8, and 10 weeks

  • Self-Concept Clarity Scale (SCCS)

    SCCS is a 12-item scale to measure the clarity of self-concept. Questions are scored on a Likert scale of 1-5 with 1 being strongly disagree and 5 being strongly agree.

    0, 2, 4, 6, 8, and 10 weeks

  • Acceptance and Action Questionnaire-2nd Edition (AAQ-II)

    AAQ-II is the second version of the Acceptance and Action Questionnaire with 7 items. Questions are scored on a Likert scale of 1-7 with 1 being never and 7 being always

    0, 2, 4, 6, 8, and 10 weeks

  • Insomnia Severity Index (ISI)

    ISI is a 7-item screening tool to measure the severity of sleep problems. Questions are scored on a 0-4 scale with different descriptions

    0, 2, 4, 6, 8, and 10 weeks

  • Client Satisfaction Questionnaire (CSQ-8)

    CSQ-8 is an easy-to-perform initial screening tool for client satisfaction with mental health services. Questions are scored on a Likert scale of 1-4 with 1 being low satisfaction and 4 being high satisfaction.

    2, 4, 6, 8, and 10 weeks

  • Digital Working Alliance Inventory (DWAI)

    DWAI is an 8-item scale to measure the working alliance between participants and the AI model revised by the Working Alliance Inventory. Questions are scored on a Likert scale of 1-7 with 1 being totally disagree and 7 being totally agree.

    6, 8, and 10 weeks

Study Arms (3)

Generated AI (Emohaa)

EXPERIMENTAL
Behavioral: Generated AI-based intervention (Emohaa)

Group ACT

ACTIVE COMPARATOR
Behavioral: group ACT

Waitlist Group (WLG)

SHAM COMPARATOR
Behavioral: wailist (delayed intervenion)

Interventions

Participants will complete the intervention process by interacting with the Wechat applet. Participants will be required to complete a 6-week self-help therapy. Participants will be required to have a 30-minute dialogue including input and reflection time with Emohaa each week simultaneously with group ACT. Participants are free to dialogue with Emohaa for the rest of the week. An independent research assistant will monitor the intervention process from the platform. If the corresponding dialogue is not completed on time each week, the participant will be reminded via WeChat to complete this session before the start of the next session in the following week.

Generated AI (Emohaa)
group ACTBEHAVIORAL

A 6-week group ACT intervention. Each group has 6-10 participants. Each session is one hour.

Group ACT

During the intervention period, participants in the WLG were only required to complete the appropriate assessments without receiving any intervention. Upon completion of the 15-day follow-up assessment, participants in the WLG could be free to choose to receive one of the two interventions. The intervention will be the same as the corresponding experimental group.

Waitlist Group (WLG)

Eligibility Criteria

Age18 Years - 25 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Adults with 18-25 ages;
  • Suffering from emotional distress (PHQ-9 \> 9 or GAD-7 \> 9);
  • Ability to use the mobile phone to interact with AI;
  • Consent to participate in the study.

You may not qualify if:

  • High risk of self-injury and suicide;
  • Presence of psychotic symptoms (i.e., delusions);
  • Serious substance use problems;
  • Other mental or physical illnesses requiring urgent medical assistance;
  • Received other psychological or pharmacological interventions in the last month

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Central University of Finance and Economics, China

Beijing, China

Location

MeSH Terms

Conditions

Anxiety Disorders

Condition Hierarchy (Ancestors)

Mental Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Private Investigator

Study Record Dates

First Submitted

December 6, 2024

First Posted

December 16, 2024

Study Start

September 20, 2024

Primary Completion

December 20, 2024

Study Completion

December 28, 2024

Last Updated

April 25, 2025

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will share

Personal contact in reliable reason

Shared Documents
ANALYTIC CODE

Locations